AzTrials
AzTrials

StrokeNCT06637839

Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation

A study testing Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program and High-Step Count Locomotor Training Program in people with Stroke, run by NYU Langone Health at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to elucidate optimal dosing for High Intensity Gait Training (HIGT) to reduce locomotor disability for those undergoing inpatient rehabilitation (IR) in the subacute phase of stroke recovery. This is a randomized controlled trial conducted at a single IR facility. Read more about this study

Who is it for?
Ages 18 to 95 years
Conditions the study is for
Stroke
What is being tested?
Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program and High-Step Count Locomotor Training Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
Jan 2027to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 95 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Primary diagnosis of stroke

Who cannot join

  • Weightbearing restrictions, uncontrolled cardiopulmonary, metabolic, infectious, or psychiatric disorders, which would preclude aerobic locomotor training
  • Estimated length of stay of less than 14 days
  • Non-ambulatory status prior to admission (unable to walk >50 meters)
  • Pregnant

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • NYU Langone Health

    New York, New York, 10016

Other trials in United States

About this study

Official title: A Randomized, Double-blind Study Comparing the Effects of Three Distinct High Intensity Locomotor Training Protocols on Locomotor Outcomes in Subacute Stroke Patients Undergoing Adult Inpatient Rehabilitation.

The purpose of this study is to elucidate optimal dosing for High Intensity Gait Training (HIGT) to reduce locomotor disability for those undergoing inpatient rehabilitation (IR) in the subacute phase of stroke recovery.

This is a randomized controlled trial conducted at a single IR facility. Investigators will randomize patients to receive one of two distinct HIGT interventions or a high step count intervention during standard care.

Conditions
Stroke
Being tested
Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program, High-Step Count Locomotor Training Program
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Moderate-Intensity Locomotor Training ProgramBehavioural

    The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.

  • High-Intensity Locomotor Training ProgramBehavioural

    The high-intensity program prescribes participants to exert at least 60% of their heart rate (HR) reserve, or a score of 16-18 on the RPE scale.

  • High-Step Count Locomotor Training ProgramBehavioural

    The high step count program prescribes at least 600 steps per session, at less than 50% or HR reserve, or less than 13 RPE.

Study groups in NCT06637839
Study groupRoleWhat they receive
Moderate-Intensity Locomotor Training ProgramExperimentalTreatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
Receives: Behavioral: Moderate-Intensity Locomotor Training Program
High-Intensity Locomotor Training ProgramExperimentalTreatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
Receives: Behavioral: High-Intensity Locomotor Training Program
High-Step Count Locomotor Training ProgramActive comparatorTreatment will be administered for 10 consecutive 1-hour sessions over a 10-day period. Therapists will deliver the assigned intervention as part of standard care.
Receives: Behavioral: High-Step Count Locomotor Training Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Berg Balance Scale (BBS) Score

    The BBS is a 14-item objective assessment that static balance and fall risk in adults. Each item is rated on a scale from 0-4. The total score is the sum of responses and ranges from ranges from 0 to 56, with lower scores indicating a higher risk of falling and lower functional mobility.

    Measured: Discharge Assessment (Day 13-14)

  2. Ten Meter Walk Test (10mWT) Time

    The 10mWT is an assessment of walking speed in meters per second over a distance of 10 meters.

    Measured: Discharge Assessment (Day 13-14)

  3. Six Minute Walk Test (6MWT) Distance

    The 6MWT is a sub-maximal exercise test used to assess walking endurance and aerobic capacity. Participants walk around the perimeter of a set circuit for a total of six minutes. The measure is the total distance covered in six minutes.

    Measured: Discharge Assessment (Day 13-14)

  4. Inpatient Rehabilitation Facility Patient Assessment Instrument (IRF-PAI) - Admission Quality Indicator (QI) Score: Transfers

    The IRF-PAI QI score is an ordinal categorical variable measuring how much assistance a patient requires to complete the task (transfer) There are six categories (1-6) ranging from complete dependence of the patient on a helper to independent completion of tasks. A score of 1 is assigned to dependent patients, while a score of 6 represents independent completion of tasks by a patient.

    Measured: Discharge Assessment (Day 13-14)

  5. IRF-PAI - Admission QI Score: Cumulative Ambulation

    The IRF-PAI QI score is an ordinal categorical variable measuring how much assistance a patient requires to complete the task (ambulation) There are six categories (1-6) ranging from complete dependence of the patient on a helper to independent completion of tasks. A score of 1 is assigned to dependent patients, while a score of 6 represents independent completion of tasks by a patient.

    Measured: Discharge Assessment (Day 13-14)

  6. IRF-PAI - Admission QI Score: Cumulative Stairs

    The IRF-PAI QI score is an ordinal categorical variable measuring how much assistance a patient requires to complete the task (stairs) There are six categories (1-6) ranging from complete dependence of the patient on a helper to independent completion of tasks. A score of 1 is assigned to dependent patients, while a score of 6 represents independent completion of tasks by a patient.

    Measured: Discharge Assessment (Day 13-14)

Secondary outcomes (5)
  1. Number of Patients Discharged at Home

    Measured: Discharge Assessment (Day 13-14)

  2. Number of Patients Discharged at Subacute Rehabilitation Facility

    Measured: Discharge Assessment (Day 13-14)

  3. Number of Steps of Locomotor Training

    Measurement of adherence to protocols.

    Measured: Discharge Assessment (Day 13-14)

  4. Time Spent in Locomotor Training

    Measurement of adherence to protocols.

    Measured: Discharge Assessment (Day 13-14)

  5. Number of Minutes Spent in Target HR Zone

    Measurement of adherence to protocols.

    Measured: Discharge Assessment (Day 13-14)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2024
  2. Study startJan 2027 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06637839
Sponsor's protocol ID
24-00889
Status last verified
Jun 2026
First submitted
10 Oct 2024
Last updated
26 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: susan.camillieri@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Questions about this trial

What is this clinical trial studying?

A study testing Moderate-Intensity Locomotor Training Program, High-Intensity Locomotor Training Program and High-Step Count Locomotor Training Program in people with Stroke, run by NYU Langone Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Susan Camillieri (212-598-6044, Susan.camillieri@nyulangone.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Berg Balance Scale (BBS) Score (time frame: Discharge Assessment (Day 13-14)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in